Moderna (NASDAQ:MRNA) Upgraded to Hold at HSBC

HSBC upgraded shares of Moderna (NASDAQ:MRNA) from a reduce rating to a hold rating in a research report released on Wednesday, Marketbeat Ratings reports. HSBC currently has $82.00 price objective on the stock.

A number of other brokerages have also weighed in on MRNA. UBS Group boosted their target price on Moderna from $143.00 to $151.00 and gave the stock a buy rating in a research report on Tuesday, May 7th. Canaccord Genuity Group lifted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a hold rating in a research report on Friday, May 3rd. Evercore ISI reissued an in-line rating and set a $120.00 price target on shares of Moderna in a report on Thursday, June 27th. Piper Sandler reaffirmed an overweight rating and issued a $157.00 price objective (down previously from $214.00) on shares of Moderna in a report on Friday, August 2nd. Finally, Needham & Company LLC reissued a hold rating on shares of Moderna in a report on Thursday, August 1st. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $123.79.

Moderna Trading Down 0.2 %

Shares of NASDAQ MRNA opened at $77.40 on Wednesday. The company has a market cap of $29.66 billion, a PE ratio of -4.94 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.91 and a current ratio of 4.09. The firm’s 50 day moving average price is $104.62 and its 200-day moving average price is $112.80. Moderna has a 52-week low of $62.55 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. During the same period in the prior year, the firm posted ($3.62) EPS. The firm’s quarterly revenue was down 29.9% on a year-over-year basis. On average, equities research analysts expect that Moderna will post -7.46 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $151.25, for a total value of $2,268,750.00. Following the completion of the sale, the director now directly owns 1,946,931 shares of the company’s stock, valued at $294,473,313.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $151.25, for a total value of $2,268,750.00. Following the completion of the transaction, the director now owns 1,946,931 shares of the company’s stock, valued at $294,473,313.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO James M. Mock sold 689 shares of Moderna stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The disclosure for this sale can be found here. Insiders have sold 330,736 shares of company stock valued at $46,330,112 over the last 90 days. 15.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. Quadrant Capital Group LLC increased its holdings in shares of Moderna by 7.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after purchasing an additional 187 shares during the last quarter. Ontario Teachers Pension Plan Board bought a new stake in Moderna in the 4th quarter worth approximately $1,358,000. Hobbs Group Advisors LLC purchased a new stake in shares of Moderna during the 4th quarter worth approximately $664,000. Illinois Municipal Retirement Fund boosted its position in shares of Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock valued at $5,519,000 after acquiring an additional 9,360 shares during the last quarter. Finally, Swedbank AB purchased a new position in shares of Moderna in the first quarter valued at $3,315,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.